---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-22-021148"
form_type: "8-K"
ticker: "ERNA"
cik: "0000748592"
company_name: "Ernexa Therapeutics Inc."
filed_at: "2022-05-31T23:59:59+00:00"
generated_at: "2026-06-25T06:03:38.341194+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Brooklyn ImmunoTherapeutics appoints interim CEO Matt Angel, CFO Andrew Jackson; CEO Federoff resigns

## Summary
- CEO Howard Federoff resigned effective May 26, 2022; received $225K bonus, $450K salary continuation, and accelerated stock options covering 1,420,095 shares.
- Matt Angel, co-founder of Factor Bioscience, appointed interim President and CEO; Factor was a Novellus acquisition counterparty that received $1.7M cash and ~2.58M shares.
- Andrew Jackson named CFO; receives $415K base salary, 40% target bonus, and a stock option grant for 664,800 shares.
- Four directors (Heather Redman, Erich Mohr, Erin Enright, Dennis Langer) will not stand for reelection at postponed annual meeting.
- 2022 annual meeting postponed to a later date; new proxy statement expected.

## SEC filing metadata
- accession: 0001140361-22-021148
- form_type: 8-K
- ticker: ERNA
- cik: 0000748592
- company_name: Ernexa Therapeutics Inc.
- filed_at: 2022-05-31T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 5.02, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/748592/000114036122021148/0001140361-22-021148-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/748592/000114036122021148/brhc10038309_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-22-021148
- JSON: https://secwatch.observer/filing/0001140361-22-021148.json
- Plain text: https://secwatch.observer/filing/0001140361-22-021148.txt

## Key facts
- Executive change
  Matthew Angel was appointed as interim President and Chief Executive Officer at Ernexa Therapeutics Inc..
  - Action: appointed
  - Role: interim President and Chief Executive Officer
  source text: On May 24 , 2022, the Board of Directors (the “ Board ”) of Brooklyn ImmunoTherapeutics, Inc., a Delaware corporation (the “ Company ”), appointed Matthew Angel as the interim President and Chief Executive Officer (principal executive officer) of the Company, which appointment became effective on May 26 , 2022, upon the effectiveness of the resignation from the Company of Howard J. Federoff, M.D., Ph.D., as described below.
  evidence_url: https://www.sec.gov/Archives/edgar/data/748592/000114036122021148/0001140361-22-021148-index.htm
- Executive change
  Howard J. Federoff, M.D., Ph.D. resigned as Chief Executive Officer at Ernexa Therapeutics Inc..
  - Action: resigned
  - Role: Chief Executive Officer
  source text: On May 24 , 2022, the Board of Directors (the “ Board ”) of Brooklyn ImmunoTherapeutics, Inc., a Delaware corporation (the “ Company ”), appointed Matthew Angel as the interim President and Chief Executive Officer (principal executive officer) of the Company, which appointment became effective on May 26 , 2022, upon the effectiveness of the resignation from the Company of Howard J. Federoff, M.D., Ph.D., as described below.
  evidence_url: https://www.sec.gov/Archives/edgar/data/748592/000114036122021148/0001140361-22-021148-index.htm
- Executive change
  Andrew Jackson was appointed as Chief Financial Officer at Ernexa Therapeutics Inc..
  - Action: appointed
  - Role: Chief Financial Officer
  source text: On May 9 , 2022, the Board appointed Andrew Jackson as the Chief Finan
  evidence_url: https://www.sec.gov/Archives/edgar/data/748592/000114036122021148/0001140361-22-021148-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.